A novel study by Canadian physicians reported that the BioSTAR biodegradable implant achieved comparable closure rates to the Amplatzer Septal Occluder in children with atrial septal defect. A novel ...
Gore ASSURED Clinical Study results through 36 months demonstrate 100 percent closure success * with the GORE ® CARDIOFORM ASD Occluder, and consistent safety outcomes † across a broad range of ASD ...
Rochester, MN - A new case series of patients with a previous stroke suggests that transcatheter device closure of patent foramen ovale (PFO) and atrial septal defect (ASD) is safe and eliminated ...
Rochester, MN - A case report of a patient who suffered erosion of an Amplatzer septal-occluder device (St Jude Medical) six years after it was implanted, resulting in cardiac tamponade and ...
Please provide your email address to receive an email when new articles are posted on . W.L. Gore and Associates announced its occluder device was approved by the FDA for percutaneous closure of ...
NEW YORK - March 12, 2019-The Cardiovascular Research Foundation (CRF) is pleased to announce that the latest issue of Structural Heart: The Journal of the Heart Team features original research ...
FLAGSTAFF, Ariz.--W. L. Gore & Associates today reported the first patient enrolled in the GORE® Septal Occluder Clinical Study evaluating the safety and efficacy of the new GORE Septal Occluder in ...
An innovative trans-catheter device closure of a secundum Atrial Septal Defect (ASD) or a hole in the centre of the wall between the two upper chambers of the heart in a 16-month-old baby girl Ovi has ...
Patients undergoing transcatheter atrial septal defect (ASD) closure did not have worsening migraines after completing a course of dual antiplatelet therapy, the CANOA investigators found. Overall, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback